TIDMFDBK
RNS Number : 4253F
Feedback PLC
16 July 2021
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 ("MAR") (which forms part of Domestic UK Law pursuant
to the European Union (Withdrawal) Act 2018). With the publication
of this announcement, this information is now considered to be in
the public domain.
Feedback plc
Bleepa agreement with CVS Equine Division
-- First private business win for Bleepa with one of UK's leading veterinary providers
-- Contract covers 20 Equine surgeries and showcases new Bleepa capabilities
-- Demonstrates Bleepa's value in new markets
London, 16 July 2021: Feedback plc (AIM: FDBK, "Feedback" or the
"Company"), the specialist medical imaging technology company,
today announces that CVS Group ("CVS"), one of the UK's leading
providers of integrated veterinary services, has appointed Bleepa
as its clinical communications platform for its Equine
Division.
Following a successful pilot trial, CVS has adopted Bleepa for
initial use in its Equine Division. Bleepa will be rolled-out
across 20 equine specialist surgeries. The current agreement will
result in increased Bleepa users, and importantly, provides scope
for a broader relationship with CVS. Furthermore, this agreement
highlights the scalability of Bleepa and the Company's ability to
target non-NHS markets by tailoring the platform accordingly.
CVS has a clear vision to be the veterinary company people most
want to work for by providing the best clinical care through great
talent, facilities and equipment. Bleepa fits neatly into this
drive to provide world-class animal care by providing their vets
with its revolutionary clinical communications app. Bleepa enables
vets in a field to securely connect with clinical colleagues for
specialist advice and guidance whilst at the animal's side.
As part of the pilot, Feedback worked closely with the CVS team
to adapt Bleepa, providing all the features needed for veterinary
service, both within the surgery but also out in the field . Until
now vets have not been able to easily acquire X-rays in a field and
share these with colleagues. Bleepa developed an image push
capability that enables X-rays to be securely pushed from the X-Ray
machine over a cellular network to the Bleepa platform. The
platform then makes these images available to specialists for
immediate review and discussion, allowing the correct treatment
guidance for the injured animal to be communicated to the vet and
be provided at first visit. This capability means that images can
now be taken in any location and can be instantly shared with
specialist colleagues for timely advice and guidance. This
technology has clear applications in both military and rural care
delivery in developing countries.
Tom Oakley, CEO of Feedback, said:
"CVS is an important partner for Feedback and we are delighted
to now be working with them officially. Their validation of our
technology and expertise demonstrates the flexibility of Bleepa
within new markets. By purchasing Bleepa, CVS have evidenced a real
commitment to empower their vets by connecting them with specialist
colleagues at the point of care, ultimately resulting in excellent
animal care at the touch of a button, anywhere in the world."
Hattie Lawrence, Equine Director at CVS , said:
"We are delighted to be working with Feedback as we roll out
this innovative technology across our Equine division. By
introducing Bleepa, we will further enhance our clinical offering
across the division and it will further enable us to give the best
possible clinical care to our patients."
-Ends-
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Allenby Capital Limited (Nominated
Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas 07980 541 893 or 07748 325 236 or
Johnson 07884 664 686
Notes to editors
Feedback plc (AIM: FDBK) is a medical imaging technology
business. Its core product, Bleepa, is a revolutionary medical
imaging communications app, providing an easy-to-use, high quality
tool to enable remote and secure communications between front-line
clinicians and teams. Importantly, it is the only CE marked medical
imaging communications platform on the NHSx clinical communications
tools framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care facilitators. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of diagnosis.
About CVS Group plc
CVS Group is one of the leading integrated veterinary service
providers in the UK, the Netherlands and the Republic of Ireland.
The business is focused on providing a high quality, people-led
service to its customers, with outstanding and dedicated clinical
teams and support staff at the core of its strategy.
The Group operates an integrated model with 528 practice sites
across its three markets, including 9 specialist referral centres
and 34 dedicated out-of-hours sites. Alongside Laboratories
(providing diagnostic services to CVS and third parties),
Crematoria (providing pet cremation and clinical waste disposal for
its practices) and Animed Direct (the Group's online pharmacy and
retail business).
The Group employs over 7,000 staff, including over 1,900
veterinary surgeons and over 2,300 nurses across its three
territories.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFMFIIEFSELW
(END) Dow Jones Newswires
July 16, 2021 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024